8-K: Regenerex Pharma Shifts Fiscal Year End to December 31

Regenerex Pharma, Inc. announced a change in its fiscal year end from March 31 to December 31, effective September 22, 2025, to align with calendar year reporting.

Summary

• Regenerex Pharma, Inc. has changed its fiscal year end from March 31 to December 31.
• The Board of Directors approved this change on September 22, 2025.
• The change is authorized by Section 6 of the company's bylaws.
• A transition report on Form 10-K will be filed for the period from April 1, 2025, to December 31, 2025.

Sentiment

Score: 5

Explanation: This is a neutral, administrative announcement regarding a change in fiscal year end. It has no direct positive or negative financial implications disclosed in the filing itself.

Positives

• Improved comparability with industry peers due to calendar year alignment.

Negatives

• NA

Risks

• NA

Future Outlook

The company will file a transition report on Form 10-K for the period from April 1, 2025, to December 31, 2025.

Management Comments

• The Board of Directors approved a change to the Company's fiscal year end from March 31 to December 31 in accordance with Section 6 of the bylaws of the Company.

Industry Context

Many companies align their fiscal year with the calendar year for ease of comparison and reporting, especially in industries with seasonal trends or where peer analysis is crucial. This move by Regenerex Pharma could simplify investor analysis against industry benchmarks.

Comparison to Industry Standards

• Aligning the fiscal year end to December 31 is a common practice among publicly traded companies, particularly those seeking to simplify financial reporting and enhance comparability with a majority of their industry peers who often follow a calendar year.
• This change could facilitate easier analysis against pharmaceutical companies like Pfizer or Johnson & Johnson, which typically report on a calendar year basis, though the filing does not specify the rationale beyond board approval.

Corporate Governance

Stakeholder Impact

• Shareholders and analysts may benefit from improved comparability of financial results with other companies that report on a calendar year basis.
• The company's internal accounting and reporting teams will need to adjust their processes to accommodate the new fiscal year end and prepare the transition report.

Next Steps

• File a transition report on Form 10-K for the period from April 1, 2025, to December 31, 2025.

Key Dates

Keywords

Regenerex Pharma, fiscal year change, Form 8-K, corporate governance, financial reporting, SEC filing, transition report, pharmaceuticals